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ABSTRACT 
 Heart failure (HF) still remains the leading cause of morbidity and mortality and 
imposes severe global affliction and enormous cost on the healthcare system. Although 
current pharmacological therapies have shown to slow down the progression of HF, but 
seems to have reached their limits in improving overall patient prognosis. Thus, an 
immediate call for novel alternate therapies are needed which act independently as well 
as in conjunction with current treatment modality. Studies were performed in the well-
established transverse aortic constriction (TAC) model of chronic pressure overload (PO) 
in mice. In the first series of studies, Male C57BL6 mice (26-28 g) were subjected to 
either sham or TAC surgery. One group of TAC mice was given daily resveratrol 
treatment (oral gavage, 100 mg/kg/body weight (bw) for 28 days starting on day 2 after 
surgery. Echocardiographic, biometric, and immunohistological analyses were performed 
on the three groups of mice which demonstrated significantly greater adverse cardiac 
remodeling and dysfunction in the TAC compared to the sham operated mice. These 
pathological changes were significantly improved by resveratrol treatment in TAC+RSV 
mice. At day 28 fractional shortening was 46.4±2.4%, 26.2±1.0%, and 35±2% in the 
sham, TAC, and TAC +RSV mice, respectively. This was reflected by lung weight/bw 
ratios of 4.8±0.5 mg/g (sham), 10.2±1.4 mg/g (TAC) and 6.2±1.5 mg/g (TAC+RSV).  
Resveratrol treatment also significantly reduced cardiac hypertrophy as determined by the 
heart weight/bw ratios (sham, 4.9±0.3 mg/g; TAC, 8.8±1.1 mg/g; and TAC+RSV, 
7.2±0.3 mg/g) as well as by measurement of cross-sectional area (CSA) 
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(sham, 108.02±12.85 µm²; TAC, 221.7±21.43 µm²; and TAC+RSV, 187±11.9 µm²). 
Likewise, the TAC protocol significantly increased fibrosis compared to the sham-
operated mice, which was attenuated by resveratrol treatment. Pro-inflammatory cytokine 
infiltration of mast cells and macrophage were found up-regulated in response to PO. 
Similarly, markers of oxidative stress such as 4-hydroxynonenal (4HNE) and 8-
hydroxydeoxyguanosine (80HdG) were up regulated while anti oxidative markers -
sodium oxidase dismutase (SOD), glutathione peroxidase (GSH) were down regulated in 
response to PO. Similar results were obtained when hypoxia induced factor alpha 
(HIF1α), including apoptosis by terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) and activated caspase-3 were assessed in TAC hearts. These TAC-
induced factors were significantly attenuated by resveratrol treatment indicating that the 
resveratrol was acting to inhibit the increased production of these stress inducible factors 
as well as able to up regulate the levels of detoxifying enzymes. In summary, these 
results demonstrate that resveratrol treatment significantly attenuates the adverse cardiac 
remodeling and dysfunction produced by the TAC protocol in C57/BL6 mice and that 
this activity is mediated, at least in part, by the inhibition of oxidative stress and hypoxia.  
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CHAPTER 1 
INTRODUCTION 
1.1 The Heart Overview 
Heart is considered to be the main engine that drives human body and is the first 
organ to be formed during embryonic development. Heart is remarkably a well-tuned 
organ and beats about two and a half billion times in an average human lifetime. Heart 
constantly keeps working even while we are at rest. Heart, blood and blood vessels make 
up the entire circulatory system. Heart is a hollow, muscular organ and consists of four 
chambers that are entirely different in its structure and function and are equipped with 
valves. Three layers of heart muscle namely endocardium, myocardium and epicardium 
plays integral role in maintaining normal homeostasis of the blood supply. Heart not only 
pumps the blood throughout the body but also supplies oxygen and nutrients that are 
essential for the normal human growth and development. Valves play a significant role in 
maintaining the proper orientation of the blood flow and preventing the backflow. Heart 
maintains its pumping mechanism by contraction and relaxation, which is due to the 
electrical conduction system generated in Sino atrial node and relayed through purkinjee 
fibers. This rhythmic contraction of the heart is essential in maintaining contraction and 
pumping blood via series of blood vessels within the heart known as coronary circulation, 
which is primarily responsible for distributing, oxygenated blood and other nutrients to 
the working heart muscle.  
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Circulatory system of the heart makes use of all the four chambers where, 
function of the right atrium and right ventricle is to collect the deoxygenated blood 
returning from the organs and tissues and pump it to lungs where it gets oxygenated. This 
oxygenated blood is then received by left atrium and left ventricle, which then pumps it 
to the organs and tissues of the body to enable them, perform their normal functions. 
Blood is ejected out of the right and left ventricle by vigorous contraction of ventricular 
muscle to the body parts during ejection, which is known as systole while diastole ensues 
during filling phase. The amount of blood pumped through the heart each minute is called 
cardiac output and is the measure cardiac performance defined by ventricular ejection. 
Contractility, preload and afterload are the three aspects by which heart maintains its 
cardiac output and performance and these aspects determine the ventricular effectiveness 
during systolic phase. Component muscle fibers of myocardium undergo shortening in 
order to increase the intrinsic strength to produce work which is referred as contractility 
while preload is referred to pre-ejection filling of the ventricular chamber affecting 
preshortening stretch of its component fiber and finally afterload is referred to as the 
force against which myocardium has to work in order to contract and eject blood. Also, 
during normal physiological condition, increased cardiac preload and afterload are 
attributed to increased and decreased ejection of blood from the ventricles respectively. 
In order to complete the cardiac cycle, heart has to undergo two main steps to achieve 
diastolic ventricular filling which consists of an early rapid filling phase where blood 
stored in the atria rushes into the ventricles and second being the forceful atrial 
contraction pushing additional blood into the ventricles before their contraction thus 
contributing significantly to afterload. 
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1.2 Left Ventricular Hypertrophy & Congestive Heart Failure –Clinical 
Significance 
Heart failure (HF), also known as congestive heart failure (CHF), is the clinical 
endpoint of several types of primary and secondary pathologies during which pumping 
ability of the heart becomes incapable of the supply at the rate proportionate to the 
demands of the body. Clinically HF is defined as a syndrome due to pathological disorder 
of cardiac structure or function such as ischemic heart disease, hypertension or several 
specific cardiomyopathies, resulting in impairment of filling and/or ejection of blood 
from the ventricles (Klein et al., 2003). Currently, CHF is the number one cause of death 
in the western world. In United States alone approximately 5 million people are suffering 
from HF at present and about half of a million new cases are diagnosed each year (Klein 
et al., 2003). Clinically patients suffering from HF with presence of obvious symptoms 
have poor prognosis with 5-year survival rate at 50% upon diagnosis (Klein et al., 2003). 
Regardless of the advancement in the diagnosis, treatment and management of HF, 
unfortunately 75% of the new cases die each year and the death toll is still on sharp 
incline (Klein et al., 2003). HF is more commonly seen in elderly people with age more 
than 65 and this underlying disorder accounts for staggering 12-15 million office visits 
and 6.5 million hospital days. In the past decade the number has increased from 
approximately half a million to nearly one million for HF as primary diagnosis and 1.7 to 
nearly 2.6 million for secondary diagnosis (Klein et al., 2003). 6-10% of these elderly 
patients are diagnosed with primary HF and approximately 80% of them are hospitalized 
(Klein et al., 2003). Treatment and management of HF is very expensive and estimated 
21-50 billion dollars are annually spent in diagnosis and treatment of HF                  
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(Klein et al., 2003). Despite all the advancement in the management and treatment of HF 
patients, heart transplant seems to be the last resort out (Dorn and Molkentin, 2004). 
Being diagnosed with HF carries poor prognosis and the mortality in the advance stages 
can be as high as 45% (Jessup and Brozena, 2003).  
No definition of heart failure is entirely satisfactory. Depending upon the etiology 
of heart failure, symptoms in patients of HF such as breathlessness, fatigue and swelling 
ankle can vary greatly with the exception of patients suffering from myocardial infarction 
(MI). Onset of symptoms is usually acute in MI patients however it can be very subtle or 
even asymptomatic and progress over weeks or even months in patients with progressive 
HF (Francis, 2001). Although causes of HF can be due hypertension, different valvular 
disease, viral myocarditis, various drugs and toxins, genetic mutation including idiopathic 
cardiomyopathy however, MI due to coronary artery disease still remains the most 
common cause of HF (Adams, 2001). It is also possible to have a heart attack without 
experiencing any symptoms at all and is known as “silent” MI. Irrespective of the cause, 
dysregulated homeostasis due to significant deterioration in cardiac structure and function 
leads to attenuation in contraction and sharp decline in cardiac output which further 
follows into thinning of ventricular wall and dilation leading to ventricle enlargement and 
increased peripheral vascular resistance (Dorn and Molkentin, 2004). All of these above-
mentioned causes significant decrease in the cardiac output due to the impaired 
contraction/relaxation eventually the heart fails to meet the metabolic demands of the 
body and overt HF occurs. Figure. 1. 
Heart undergoes left ventricular remodeling in order to overcome the deficiency 
in the function of the ventricles to maintain required cardiac output                       
 5 
(Heineke and Molkentin, 2006). Heart does this by undergoing hypertrophy. Initially, this 
mechanism of ventricular remodeling can be a beneficial compensatory response 
resulting in enlargement of myocyte as a means of preserving cardiac output thereby 
decreasing wall tension (Lorell and Carabello, 2000). However, this pathological 
hypertrophy possesses serious risk factor for cardiovascular disease and sudden death 
(Haider et al., 1998; Levy et al., 1990; Schillaci et al., 2001). In order to cope with the 
hypertension-induced pressure-overload, the heart undergoes two main remodeling 
patterns of hypertrophy namely concentric and eccentric hypertrophy during which 
change in the ventricular chamber size and increase in fibrosis ensues (Heineke and 
Molkentin, 2006). During concentric hypertrophy, ventricular chamber size is increased, 
thinning of wall, apoptosis followed by extensive cardiac fibrosis results. Characteristics 
of concentric hypertrophy at cellular level is increased synthesis of sarcomeres in parallel 
that results in increased cellular width, while dilation is characterized by laid down of 
sarcomeres in series that results in increased myocyte length (Heineke and Molkentin, 
2006). Due to the poor ventricular compliance and impaired relaxation, diastolic 
dysfunction can result if hypertrophy persists (Zile and Brutsaert, 2002). A number of 
other factors such as from genetic defects, MI can also directly damage the cardiac 
muscle and cause this type of remodeling (Heineke and Molkentin, 2006).  
Despite of the fact that there are a number of key players involved in the process 
of progression of left ventricular remodeling and might be mediating their role through 
various pathways, substantial evidence points towards the activation of endogenous 
neurohormonal systems that may be playing an important role in cardiac remodeling and 
thereby in the progression of HF. During the condition of decreased cardiac output, this 
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activation of neurohormonal system is thought to play protective effect by 
vasoconstriction, salt and water retention, and adrenergic stimulation of the heart thereby 
compensating for the decreased cardiac output and maintaining the hemodynamics. 
Under certain life threatening conditions such as hemorrhage, this short-term adaptive 
mechanism may seem to be beneficial however long term activation is maladaptive in the 
heart. By retaining excess sodium and water, it causes excessive increase in the 
hemodynamic stress on ventricles as well as exert direct toxic effects on cardiac cells and 
stimulate myocardial fibrosis, which can further alter the architecture and impair the 
performance of the failing heart (Harris, 1983; Packer, 1992). Other factors such as 
elevated circulating or tissue levels of norepinephrine, angiotensin II, aldosterone, 
endothelin, vasopressin, and cytokines is found in HF patients, and the action of these 
agents working alone or in concert can further deteriorate the structure and function of 
the heart. Chronic stress on the myocardium causes deterioration of left ventricular 
function and even in the absence of new insult, it progresses further resulting in chamber 
dilation and decreased cardiac output. Further deterioration in observed in the function of 
valves, which causes back flow of blood resulting from increasing hemodynamic 
overload. Cardiac remodeling is an ongoing pathological process, which keeps 
progressing and worsening of symptoms irrespective of the continuous treatment and 
management of patient with HF.  
Systolic or diastolic heart failure can now be well characterized with the use of 
advanced echocardiograms. Due to the characteristics of diastolic heart failure such as 
hypertension and pulmonary congestion, it still remains echo insensitive however 
characteristics of systolic failure is very sensitive to echocardiogram and the 
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characterized by left ventricular enlargement, reduced contractility and ejection fraction 
followed by pulmonary congestion.  
Signs and symptoms are very obvious in HF patients only in later advanced stages 
and may exhibit as pulmonary congestion and peripheral edema due to fluid retention 
thereby leading to breathlessness and reduced exercise tolerance, which is manifested as 
fatigue. HF is not a single disease but rather a complex syndrome resulting from a 
manifestation of different cardiovascular disorders, therefore cannot be treated with 
single cure. Exhibition of chief clinical signs and symptoms and the stage of the disease 
should be taken into account and the treatment regimen should be tailored to their 
individual characteristics. Figure 1.2 
According to the American heart association and American college of cardiology 
guideline published in 2001, prevention and treatment of patients with HF can be 
classified into four stages namely: Stage A- patients suffering from hypertension, 
coronary artery disease (CAD), or patients who recently had a myocardial infarction (MI) 
fall under this stage These HF do have some structural abnormality in their 
cardiovascular system but do not exert symptoms. Stage B- patients diagnosed with 
structural heart disease but do not express signs of heart failure fall under this stage. 
Structural abnormality of the heart is readily detectable on the echocardiogram and mild 
to moderate expression of symptoms. Stage C- patients showing obvious signs of heart 
failure with marked clinical manifestation of sign and symptoms such as dyspnea on 
exertion and fatigue and eventually stage D includes patients with end-stage heart failure 
awaiting transplantation and their mobility is very restricted and are under mechanically 
assisted devices to maintain CO.  
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1.3 Cardiac Hypertrophy And Heart Failure - The Molecular Basis   
One of the major questions in hypertrophy and HF research is the mechanism by 
which cardiac cells sense stretch, and significant progress has been made in the recent 
past regarding it. Despite of the identification of the major players of hypertrophic 
signaling in the myocardium, it is still unclear why and how the frequent transition from 
hypertrophy to failure occurs. Many pathways have been identified that leads to 
hypertrophy however the most vital and most studied pathway is mitogen activated 
protein-kinase pathway (MAPK). Hypertrophic cardiomyocyte growth is due to the 
activation of signaling pathway that in turn causes reactivation of fetal genetic 
program creating a chronic condition where these responses elements further exaggerates 
the heart damage leading to deterioration of function (Lorell and Carabello, 2000). 
Initially cardiomyocytes were thought to be incapable of differentiating, however the 
hypothesis has chanced in the recent past. The term cardiac hypertrophy is defined as an 
increase in the cellular mass in response to growth stimuli, which is thought to be an 
adaptive response during the common disorders such as pressure or volume overload, 
loss of cardiac mass due to MI etc. Cardiac hypertrophy is usually seem to accompany 
pathological processes such as MI, valvular disease, ischemic disease which can 
ultimately result in heart failure however, it can also occur in absence of other 
cardiovascular diseases. Initially cardiac hypertrophy is considered to a compensatory 
stage in response to stress signals such as hypertension or myocardial infarction and 
protects the heart by decreasing energy consumption as well as decreasing the systolic 
wall stress (Grossman et al., 1975). However, if the chronic stress persists for too long, 
arrhythmia and sudden death followed heart failure is inevitable. A pathological 
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structural and functional change in the heart occurs due to persistent stress signals that 
cause cardiac remodeling. Remodeling involves not only the cardiomyocytes but also 
cardiac fibroblasts, elements of the interstitial matrix, and the entire coronary vasculature. 
Healthy or unaffected cardiomyocytes now has to take over the function of the affected or 
injured part making up for the loss as an adaptive response. This can be usually seen in 
condition such as MI. Cardiac remodeling at cellular and molecular level involves 
changes from physiology of the heart all the way to gene level.  
Activation of the rennin-angiotensin-aldosterone system (RAAS) as well as 
adrenergic and cytokine pathways are some of the secondary changes associated along 
with above mentioned primary remodeling which heart has to deal with. Sarcomeres are 
the force generating units, which undergo production of more sarcomeres through a gene 
transcription modification biochemical event in the nucleus upon increased force on the 
cardiomyocyes. This modification of gene transcription can also be achieved through 
various stimuli, which activates distinct receptors in the cardiomyocyte. Figure. 1.3.  
G-protein-coupled receptors, receptor tyrosine kinases and cardiotrophin receptors 
are some of the most studied receptor pathways which upon activation operates through 
signaling pathways and mostly comprises of series of phosphatases and kinases. The 
phosphatase pathways include calcineurin (PP2B), protein phosphatase 1 and protein 
phosphatase 2A (PP2A) while the kinase pathways include protein kinase C, protein 
kinase A, calcium-calmodulin-dependent kinase and mitogen-activated protein kinases.  
It has been shown that cardiac transcription factors are responsible for the 
differential gene expression induced by hypertrophic stimulation. Therefore hypertrophy 
of cardiomyocytes occurs when there is a sudden change in the transcriptional programs 
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mediated by cardiac signaling pathways and convert extracellular signals into 
intracellular signals. GATA family, (MEF2) family, and the homeobox factor 
(Csx/Nkx2.5) family are some of the most studied families of cardiac transcription 
factors and the genes that encode regulatory or structural proteins of the cardiomyocyte 
by eliciting changes in other cell types in the heart are regulated by these cardiac 
transcription factors which are transcriptional activators or repressors that regulate the 
expression of cardiac genes (Kolodziejczyk et al., 1999; Liang et al., 2001; Takimoto et 
al., 2000; Toko et al., 2002). 
1.4 Contraction, Relaxation And Regulation Of Failing Heart 
 
Heart muscle is remarkable and beats about 70 beats per minute and about 
100,000 times per day. Contraction and relaxation of the heart generate the force required 
to maintain the cardiac output. Cardiomyocyte contains thick and thin filaments namely 
actin and myosin. Sleeves of sarcoplasmic reticulum surround the myofilaments within 
the myocyte. Calcium plays a vital role in the maintenance of cardiac contractility and it 
is the second common messenger and the central regulator of cardiac contractility. Under 
normal physiological the exchange of sodium, potassium and calcium occurs in harmony 
and is well regulated to maintain the efficient contraction. The calcium release channels 
from heart and skeletal muscle SR are similar but not identical. Important differences 
distinguish the calcium release machinery in heart from that of skeletal muscle. The role 
of calcium as the key factor in coupling cardiac excitation (depolarization) and 
contraction. The calcium ion is the activator of chemically bound energy to mechanical 
energy in all types of contractile structures, from microfilaments to striated muscles. 
Strength of cardiac contraction can be varied by either altering the Ca2+ concentration or 
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by altering the sensitivity of the myofilaments to Ca2+ and this can be achieved by 
maintaining the intracellular calcium concentration by channels, pumps and exchangers. 
Sarcoplasmic reticulum in cardiomyocytes contains large internal store of Ca2+ and is 
released in large amounts following a small increase of extracellular Ca2+ into the 
cytosol. This phenomenon is called Ca2+ induced Ca2+ release. The myofilament 
proteins undergo conformational changes following the release of cytosolic calcium 
increase thereby achieving contraction. However, this cytosolic Ca2+ must then be 
removed in order to achieve a proper relaxation. Changes in the concentration of the 
Ca2+ homeostasis and or alterations in the contractile proteins may be one of the chief 
reasons for the likely cause of decreased contractility associated with heart failure 
(Piacentino et al., 2003). Figure 1.4 
1.5 Current Treatment Modalities For Hypertensive Heart Disease And 
Heart Failure 
HF has become increasingly prevalent as the population ages and has reached the 
epidemic proportion in USA as well as around the globe. HF possesses a substantial 
socio-economic burden on the families suffering from it as well as on the economy of the 
country. A wide range of pharmacological agents are employed in the prevention, 
management and treatment of patients suffering from HF. Popular and most widely used 
pharmacological agents such as vasodilators, positive inotropic agents, beta blockers, 
diuretics and inhibitors of neurohormonal activators have been able to address some of 
the cellular mechanisms of HF so far however, they fail to completely achieve their 
intended goal in stabilizing or regressing the disease progress and improving the quality 
of life by minimizing the pathological symptoms and enhancing the survival. Initially, 
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upon injury or stress, the feed back mechanism of the human body tries to play a 
compensatory role by activating a series of neurohormonal systems.  
One example of such compensatory neurohormonal activation is the activation of 
renin angiotensin aldosterone system (RAAS). In the event of decreased cardiac 
contractility, the cardiac output declines significantly thereby being unable to meet up 
with the demands of the body. RAAS causes retention of salt and water thereby 
expanding the blood volume and maintaining the cardiac output. This compensatory 
response is thought to be beneficial in the initial stages however, long-term activation of 
this neurohormonal system causes severe hemodynamic pathology leading to renal 
function deterioration and eventual HF (Rouse and Suki, 1994; Schrier and Abraham, 
1999). Increased pressure in diastolic filling due to the excessive expansion of fluid 
causes further severe pathological stress on the heart leading to ventricular hypertrophy 
and cardiac remodeling. Diuretics are the drugs of choice under condition and their action 
is mainly on the kidney. It causes the elimination of salt thereby preventing water 
retention and eventually decreasing the hemodynamic load placed on the heart. Another 
method by which compensatory mechanism of the heart tries to maintain the necessary 
cardiac output is by vasoconstriction and increasing the systemic vascular resistance. This 
significant increase in the peripheral vascular resistance causes increased afterload on the 
heart thereby imposing even greater pressure on LV against which it needs to eject the 
blood (Cohn and Franciosa, 1977a, b; Kass and Kelly, 1992). This vasoconstriction then 
becomes pathological problem and therefore needs to be relieved. Drugs that mediate 
vasodilation by increasing the diameter of the vessel should be employed. A number of 
commercially available potent vasodilators are the drug of choice. These vasodilator act 
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on the vascular smooth muscle cells by increasing the intracellular level of cGMP and 
inducing vasorelaxation thereby improving coronary blood flow as well as reducing 
ventricular filling pressure and wall stress (Fallen et al., 1995; Hare et al., 1995; Harrison 
and Bates, 1993).  
Upregulation of endogenous vasodilators such as ANP and BNP have been 
documented in patients suffering from HF (Vesely et al., 1994; Vesely et al., 1995) and 
also their positive roles in improving cardiac contractility, cardiac output and clinical 
status have been reported (Colucci et al., 2000; Mills et al., 2002). Apart form the 
pathological nuerohormonal cascade activation, heart also has to deal with deteriorated 
contractility leading to cardiac output. A choice of positive inotropic agents that are 
capable of reducing the hemodynamic overload from the heart in patients suffering from 
HF is an ideal choice to increase the cardiac contractility. One such drug of choice is 
Digoxin. It is a cardiac glycoside and the mechanism by which it works is by inhibiting 
Na/K ATPase pump thereby increasing the intracellular sodium which can be used for the 
exchange of calcium thus causing the improvement in the cardiac contraction and 
achieving optimum cardiac output (Blaustein, 1993; Hauptman and Kelly, 1999). 
Another similar pharmacological agent performing through different route to improve the 
cardiac contractility is adrenergic agonist. It mediates its effect by increasing the 
intracellular calcium level by binding to G-protein coupled receptors on the sarcolemma 
membrane thereby improving cardiac contractility. Following the increase in the level of 
intracellular cAMP, PKA is activated which causes the release of voltage gated calcium 
ion channels thereby even more pronounced cardiac contractility is achieved.  
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Another strategy of increasing intracellular calcium level is by relieving the 
inhibition of Ca2+-ATPase in sarcoplasmic reticulum (SR). Inhibition of PDE causes 
upregulation of cAMP. It has been shown that in SR, conversion of cAMP into AMP by 
PDE III takes place thereby even more PKA activation can be observed in the presence of 
excess cAMP that in turn causes phosphorylation of phospholamban and finally reliving 
the inhibition of Ca2+-ATPase pump in SR (Forfia et al., 2007; Koss and Kranias, 1996; 
Leroy et al., 1996; Movsesian et al., 1991). In addition to above, inhibition of PDE III 
and V can also cause vasodilation and one such drug of choice is sildenafil (Forfia et al., 
2007; Jiang et al., 1992). Angiotensin II has been known to cause smooth muscle 
proliferation, vasoconstriction thereby causing cardiac hypertrophy (Inagami, 1999). 
Drug of choice to inhibit such pathological effect can be achieved by using angiotensin 
converting enzyme inhibitor (ACEI), which prevents the formation of Ang II within the 
RAAS system thus preventing vasoconstriction and hypertrophy (Inagami, 1999). A need 
of other players such as Angiotensin receptor blocker (ARB) and aldosterone antagonist 
is essential because HF patients overtime develop resistance against ACEI. Thus this new 
drugs help to protect the heart further and improve cardiac contractility thereby 
increasing CO (Gottlieb et al., 1993; Havranek et al., 1999; Mazayev et al., 1998). 
However, every new drug has its own side effect along with its protective functions. 
Pathological effects such as profibrotic and arrhythmic effects of aldosterone cannot be 
overcome by either ARBs or ACEI, therefore an adjunct therapy using ARB is employed 
(Pitt, 1995; Ramires et al., 2000; Weber et al., 1993). As a compensatory response to 
increase the CO by increasing the cardiac contractility, the increase in the sympathetic 
output in response to adrenergic signaling is initiated (Haber et al., 1993). Desensitization 
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of this system is observed in patients with advanced stage HF as an adaptive mechanism 
by down regulating beta 1 however, activation of this pathway again is pathological in 
later stages as it causes increased overload on ventricular wall leading to ventricular 
dilation, contractile dysfunction and cardiomyocyte apoptosis (Bristow, 1997, 2000b; 
Bristow and Gilbert, 1995; Eichhorn and Bristow, 1996). Therefore by employing beta 
blockers, the harmful effects of NE can be attenuated significantly hence improvement in 
the systolic function as well as reversal of cardiac remodeling can be achieved (Abraham 
et al., 2002; Lowes et al., 2002). Figure 1.5 
Irrespective of the significant advancement in the medical field in the areas of 
diagnostic tools as well as development of novel pharmacological agents that can act 
individually or in concert with other agents to mediate their potential positive effect in the 
treatment of underlying pathology of HF. None have been efficient enough to stop the 
progression of disease, therefore a much more potent agent is needed to combat such 
disease that carries dismal prognosis.  A novel alternate therapy that can be used as 
adjunct with existing ones or that can act alone effectively in managing the 
neurohormonal cascades and improve overall quality of life in patients with HF is 
needed. One such potential drug has been recently discovered which shows promising 
effectiveness in the treatment and management of HF by mediating anti-oxidative 
1.6 Pathogenic Effects Of Oxidative Stress In Heart Failure 
Increase or decrease in the level of antioxidant protection depends on the oxidant 
and reactive oxygen species (ROS) generation during oxidative stress. Due to the 
variation of the redox condition influenced by ROS, a number of biological processes are 
influenced which causes changes in the signal transduction cascades upstream of nuclear 
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transcription factor (Palmer and Paulson, 1997). Characteristics of ROS are free radicals 
containing oxygen atoms and they are known to produce free radicals such as hydrogen 
peroxide, superoxide and peroxynitrite. A number of biological molecules such as 
macrophages, neutrophils and xenobiotics try to maintain the cellular defense preventing 
ROS by phagocytosis or by cellular respiration (Abe and Berk, 1998; Klaunig and 
Kamendulis, 2004; Palmer and Paulson, 1997; Pathak et al., 2005; Zangar et al., 2004). 
However, excessive ROS production due to any injury or stress causes the alteration in 
the macromolecules, essential proteins and DNA resulting in cell death. By inducing 
MAPK family and PKC pathway, ROS has been known to mediate a number of 
physiological as well as pathological stimuli such as inflammatory cytokines, angiotensin 
and ionization radiation. Depending upon the content of critical cysteine residues, 
different cell types exhibit different sensitivity to oxidation and ROS can regulate their 
essential biochemical events such as phoporylation/dephosporylation of proteins by 
changes in their structural confirmation thereby inducing growth, differentiation and even 
apoptosis of cell (Sundaresan et al., 1995). Another potential pathological property of 
ROS is shown to be able to cause chromosomal aberration leading to cellular mutation 
and carcinogenesis at low concentration while higher concentration causes cytotoxicity 
and cell death (Abe and Berk, 1998; Klaunig and Kamendulis, 2004; Palmer and Paulson, 
1997; Pathak et al., 2005; Zangar et al., 2004). 
Cardiac remodeling has been established as a fundamental process in the 
progression of HF. Cardiac remodeling is characterized by a series of alteration in the 
structure and function brought in by the changes in the gene and protein expression both 
in extracellular matrix (ECM) and individual cardiomyocyte. Despite the extensive 
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clinical and experimental studies to uncover the mechanisms that underlie the poor 
prognosis of HF patients, satisfactory treatment has not been achieved. This provides a 
strong reason to pursue this field to the utmost extent and eventually be able to elucidate 
the pathways that would be therapeutically targeted to improve the outcome of millions 
of HF patients. Oxidative stress and activation of matrix metalloproteinases (MMPs)- a 
family of enzymes capable of degrading all the matrix components of the heart, have 
received an increasing attention in the HF research area. Under normal physiological 
conditions, there exists a great balance between ECM formations and its degradation and 
MMP are critical in determining this balance. Inappropriate activation of MMPs and low 
levels of their inhibitors TIMPs have been shown to cause cardiac remodeling and 
influence the shape and size of the ventricular chamber. Similarly, oxidative stress due to 
injury of any kind on the heart has been shown to induce cardiac remodeling and HF and 
this has been shown in the clinical settings of HF (Sundaresan et al., 1995). Although 
pharmacological inhibition of MMPs by employing commercially available inhibitors 
such as TIMPs have been shown however, control of oxidative damage is not manageable 
by TIMPs and the patients with advanced HF show marked elevated levels of oxidative 
stress markers which again positively correlates with the role of oxidative stress in HF. It 
seems that an obvious mechanism of myocardial dysfunction is through oxidative stress, 
which causes cellular and protein function deterioration thereby leading to cardiac 
impairment and eventually death through apoptosis and necrosis. Figure 1.6. 
Toxicity and pathogenicity of ROS depends on its concentration, the site of 
production as well as over all cellular redox status (Finkel, 2011). A potential hypothesis 
can be developed by looking at the roles of ROS in the HF as well as its potential to 
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influence ECM remodeling by activating MMPs (Spinale, 2002). A clinical study 
employing human subjects who have undergone coronary artery bypass surgery showed a 
strong link between oxidative stress, MMP activation and LV dilation (Kameda et al., 
2003). By this study, the authors were able to successfully demonstrate a positive 
correlation between the level of oxidative stress, activation of MMPs and cardiac 
remodeling which are characterized by increased pericardial levels of 8-isoprostane, 
MMP-2 and 9 and increased left ventricular end diastolic volume. Another mechanism by 
which ROS exerts its pathological effect on the cardiovascular system is by counteracting 
the endogenous nitric oxide (NO) production. NO is a potent antioxidant and it mediates 
its effect by vasodilation. When the concentration of ROS increases excessively, the NO 
cannot maintain their protective role anymore thereby causing vascular endothelial 
dysfunction. ROS further reacts with NO causing the production of peroxinitrite, which 
again is a harmful reactive oxygen species. These peroxinitrite are further capable of 
modulating diverse intracellular signaling pathways therefore causing pathological effects 
(Finkel, 2011). Some of the key proteins involved in the myocardial excitation-
contraction coupling are ion channels, calcium release channels from sarcoplasmic 
reticulum and myofilaments and these proteins are no exceptions in escaping redox 
signaling (Byrne et al., 2003).   
Effects on cellular energetics exerted by ROS as well as chronic changes in the 
cellular phenotype and pathophysiology of HF has been shown to be mediated by ROS 
(Byrne et al., 2003). Not only activation but also increased MMP expression has been 
reported by ROS (Spinale, 2002). Although attenuation of ROS by chronic treatment with 
ROS scavengers can lead to deactivation of redox sensitive signaling pathway (MAPK, 
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NFkB) thereby preventing cardiomyocyte hypertrophy however, targeting the potential 
source of ROS may be a better approach (Byrne et al., 2003). To date, some of the most 
potential sources of ROS have been identified which include infiltrating inflammatory 
cells, mitochondria, xanthine oxidase and important of all NADPH oxidase. Contractile 
dysfunction in advanced HF due to mitochondria derived excessive ROS production in 
cardiomyocytes have been demonstrated in the experimental models of HF. Similarly, 
human and canine study have shown elevated levels of xanthine oxidase in advanced HF 
stage. These above observations were further confirmed by a study in human subjects 
performed by Kameda et al where they demonstrated lower level of MMP and 8-
isoprostane achieved by treatment with xanthine oxidase inhibitor (Kameda et al., 2003). 
Apart from xanthine oxidase, an important source of ROS production is through NADPH 
oxidases- a family of complex enzymes. Initially they were characterized in neutrophils 
however, recent reports suggests its wide expression. As mentioned NADPH is a major 
source of ROS production and any pathophysiological stimuli in heart such as pressure 
overload (PO), volume overload (VO), TNF alpha, Ang II or alpha adrenergic agonist can 
cause serious ROS production through NADPH oxidases (Griendling et al., 2000). 
Several human and animal experiment studies have well implicated the pivotal role of 
NADPH oxidases in the ROS generation and pathogenesis of HF (Heymes et al., 2003; Li 
et al., 2002; Maack et al., 2003). Additional evidence is supported by the genetic 
knockdown of NADPH oxidase gene in rodent model and elucidating its role in Ang II 
induced cardiac hypertrophy and interstitial fibrosis (Bendall et al., 2002). Due to 
numerous pathological effects mediated by ROS, it certainly has a bad press however, it 
should be noted that net effect of ROS can be maladaptive by one enzymatic source but 
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can be adaptive through the next. Therefore ROS plays a clinical role in the CVD process 
and its progression to HF. 
1.7 Resveratrol And Its Diverse Protective Effects 
Since HF is not a single disease with a single etiology but rather a complex 
disorder resulting from a number of pathological conditions, therefore the treatment of 
HF cannot be achieved by specific targeting of certain pathways. It has to be done 
employing an agent that has a broad spectrum of coverage. Over the past several decades, 
a number of extracts from fruits and plants have been screened and studied in various 
experimental settings that may be beneficial to human health by responding to injury or 
infection as defense system. Among these phytochemicals, a non-flavonoid polyphenol 
resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a one such example. Fig. 1.7 Resveratrol 
has a long history and was first identified in 1940 in the roots of white hellebore, and 
later in the dried roots of Polygonum cuspidatum (Cichewicz et al., 2000; Vastano et al., 
2000). However, this stilbene polyphenol was discovered only in 1976 in the leaf 
epidermis and the grape skin (Langcake and Pryce, 1977). Fig 1.8  
By various researchers in diverse pathological conditions, resveratrol has been 
shown to have diverse bioactivities (Aggarwal et al., 2004; Fremont, 2000) Table 1.1 
including but not limited to modulation of antioxidant, lipid profile, anti-cancer, anti-
inflammatory, anti-glycemic, anti-platelet aggregation, anti-viral, anti-bacterial and 
including antioxidant activity, vasorelaxing activity, dyslipidemia and obesity, the ability 
to protect endothelial function and much more. By acting on RAAS system, resveratrol 
has been shown to eliminate salt and water retention thereby decreasing the pressure 
overload from the heart as well as inducing levels of endogenous anti-oxidant NO and 
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causing vasodilation thereby attenuating the hypertension and cardiac remodeling. 
Similarly resveratrol keeps a good check on lipid profile by various mechanisms and 
regulates level of HDL/LDL thereby attenuating dyslipidemia and obesity together with 
formation of atherosclerotic plaques. Resveratrol also increases the sensitivity of glucose 
to insulin in beta cells maintains check on diabetes. Resveratrol also have been shown to 
cause multiple other beneficial effects pertaining to CVD such as attenuating valvular 
disease, metabolic syndrome etc thereby ultimately leading to prevention of development 
and attenuation of progression of HF (Aggarwal et al., 2004; Aziz et al., 2003; Dong, 
2003; Fremont, 2000; Gusman et al., 2001; Jang et al., 1997; Savouret and Quesne, 2002; 
Signorelli and Ghidoni, 2005).  
Resveratrol has been credited for the low incidence of heart disease in France, 
popularly known as “French Paradox” (Pace-Asciak et al., 1995). Since the discovery of 
resveratrol, it has been widely used in a number of experimental settings due to the 
potential of resveratrol in prevention or regression of various illnesses such as CVD, 
cancer, and ischemic injury. This has caused the number of resveratrol citations in 
PubMed to increase dramatically. Moreover, resveratrol has been shown to increase the 
longitivity in various organisms and is thought to mediate this action by activating SIRT 
1- a gene widely studied in context of ageing (Baur and Sinclair, 2006). 
 Fresh grape skins are the major source of resveratrol containing 50-100 mg/g 
while red wine contains 10 µM resveratrol on average. Long before the actual discovery 
of resveratrol, folk medicines in Asia have been using these plants as a part of their herb 
for the treatment of various illnesses such as in inflammation and arthritis. Resveratrol is 
produced in plants in response to radiation injury or fungal infection. Chemical structure 
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of resveratrol is also an important aspect of this compound to be able to bind to diverse 
molecules and their receptors in order to mediate its wire array of protective effects. It 
consists of two aromatic rings linked by a styrene double bond with two hydroxyl groups 
at the 3 and 5 positions of one ring and one hydroxyl group at the 4’ position of the other 
ring. Resveratrol is more soluble in DMSO than in water and has a melting point of 253-
255°C and molecular weight of 228.25. Cardiovascular disease is a serious global health 
issue and possesses huge socio-economic burden. Since CVD is a syndrome rather than 
an isolated disorder resulting from various pathological processes and multiple etiologies 
therefore using a pharmacological agent that has the potential to target multiple molecular 
mechanisms may yield better therapeutic efficacy as opposed to the one that is very 
selective. Since resveratrol has been shown to possess protective potentials and achieves 
multi-targets related to CVD, it would be logical to cut down the cost by taking as few 
drugs as possible while maintain the similar level of efficacy through one potential drug. 
(Baur and Sinclair, 2006; Opie and Lecour, 2007).  A number of in vivo and vitro studies 
of animal models in regards to CVD have been done and resveratrol has been shown to 
mediate protection against ROS and preserve cardiovascular function making it a novel 
drug of choice for the treatment of HF. 
1.8 Mechanism By Which Resveratrol Mediates Oxidative Stress  
Until recently, it was highly debated as to whether resveratrol’s primary 
protective effect is mediated by acting as a radical scavenging antioxidant or by inducing 
the endogenous antioxidant that are already present in the body. The reaction by which 
resveratrol acts as a radical-scavenging antioxidant is shown: Res-(OH)3 + R· → Res-
(OH)2O· + RH, in this reaction, Res-(OH)3 represents resveratrol while R· represents free 
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radical (Karlsson et al., 2000). Res -(OH)2O is the unpaired electron of resveratrol which 
delocalizes over aromatic ring thereby making resveratrol ‘s reactivity poor. Structural 
study mentioned above clears the methodical doubt of how resveratrol counteracts ROS 
and is therefore by upregulating endogenous cellular antioxidants rather than direct 
scavenging activity of ROS (Spanier et al., 2009). Figure 1.9. Several published studies 
have shown sufficient evidence regarding the inhibition of ROS by resveratrol and is 
shown to be primarily mediated by attenuating pro-oxidative genes (NADPH oxidases 
and myeloperoxidases) (Baur and Sinclair, 2006; Dolinsky et al., 2009; Spanier et al., 
2009) and in addition also by inducing anti-oxidative enzymes like superoxide dismutase 
(SOD), glutathione peroxidase (GSH-Px) and catalase, (Spanier et al., 2009; Tanno et al., 
2010; Thirunavukkarasu et al., 2007; Ungvari et al., 2007).  SOD is located in 
mitochondria and resveratrol has been shown to regulate the level of this anti-oxidant by 
acting on mitochondrial electron transport chain thereby attenuating ROS production 
(Tanno et al., 2010). ROS has been shown to cause oxidative stress in the cells by 
inducing lipid peroxidation and resveratrol counteracts this pathological effect by 
chelating transition metallic copper that is responsible for lipid peroxidation and 
generating free radicals (Belguendouz et al., 1997; Ferretti et al., 2004). Another method 
by which resveratrol has been shown to counteract the ROS is by upregulating stress 
response protein heme oxygenase (HO-1) (Thirunavukkarasu et al., 2007; Ungvari et al., 
2007). By modulating the deacetylation of endothelial nitric oxide synthase (eNOS) and 
inducible NO synthase (iNOS), resveratrol has been shown to  upregulate the level of 
plasma nitric oxide thereby attenuating ROS induced oxidative stress (Arunachalam et 
al., 2010; Csiszar et al., 2009; Wallerath et al., 2002; Zou et al., 2003). NO has been 
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shown to have more more affinity for O2 – compared to SOD and during the reaction of 
iNOS with O2 −, peroxynitrite is generated, NO has been shown to react with –SH group 
of thiol and ascorbate and eliminate O2 therefore resveratrol/NO pathway plays vital role 
in elimination of O2 − (Hattori et al., 2002). Table 2. 
1.9 Anti-inflammatory Response Of Resveratrol 
 Traditional viewpoint regarding inflammation is depicted as a response developed 
to protect against infection and tissue injury and to repair damaged tissue. Depending 
upon the context, inflammation can be both beneficial as well harmful. Current view of 
inflammation describes it as an adaptive response to restore interrupted tissue 
homeostasis. Inflammation is mediated by tissue resident macrophages or other 
inflammatory cells. The inflammatory response however is a very complicated 
interaction of various inflammatory cells both from innate and acquired immune system. 
A controlled inflammation can be beneficial however, uncontrolled inflammatory 
response can be very detrimental and the outcome is tightly associated with various 
determinants. Under normal physiological conditions, inflammatory cells act as host 
defense. Innate immune players such as neutrophils, monocytes and macrophages all 
impart their protective effects by phagocytosis. Adaptive immune system however is 
mainly able to distinguish body’s own vs foreign and eventually clear out the pathogen. 
These cells are B, T and dendritic cells along with macrophages. However under 
pathological conditions, they secrete histamine and sertonins degraded products and 
degranulation in cells are triggered. Similarly proteolytic enzymes such as tryptase and 
chymase cause degradation of ECM as well thereby initiating cardiac remodeling. 
 A number of studies in the heart have focused on interrelation between 
 25 
inflammation and fibrosis that ultimately causes damage to cardiomyocyte and eventual 
death by apaoptosis. One such example of experimental study is during Ang II induced 
hypertension and activation of inflammatory response leading to cardiac remodeling. 
Under condition of pressure overload, these macrophages and mast cells have been 
shown to dramatically increase in their number and cause fibrosis. Due to these reasons 
of inflammation and the pathological mechanisms that underlie the harmful process of 
HF, it has gathered a significant attention in scientific community. Inflammation is not an 
occurrence due to a single etiology nor a single inflammatory cell type causes the entire 
process. A number of pathological conditions such as hypertension, diabetes, obesity, 
neurohormonal factors, radiation exposure as well as autoimmune all can trigger the 
process of pathological inflammation. Because of the significance of inflammation in 
these pathological processes, it has always been closely studied with heart diseases. One 
such example is during atherosclerosis, which is characterized by not only lipid 
deposition in the arterial wall but also subsequent activation of cascade of inflammatory 
response. These cells further causes ECM degradation and weakening of fibrous cap of 
the athromatous plaque which can eventually rupture to cause coronary artery disease, MI 
and even sudden death (DeMarco et al., 2010). Under such conditions of cellular injury 
potentiated by HTN, excessive ROS generation through NADPH is reported. These ROS 
further aggravates the pathological stimuli causing even greater adverse cardiac 
remodeling (DeMarco et al., 2010; Rizvi, 2010). Fortunately resveratrol has been shown 
to interfere with the release of inflammatory mediators, suppressing macrophages, T 
cells, B cells activity thereby mediating anti-inflammatory activity and protecting the 
heart (Fremont, 2000; Sharma et al., 2007). Resveratrol does this by inhibiting COX and 
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its subcomponents COX 1 and 2 that are required for the conversion of arachdonic acid 
into prostanoids and thromboxane. Resveratrol acts as a anti-platelet aggregation agent 
via COX 1 (Fremont, 2000; Jang et al., 1997; Szewczuk and Penning, 2004) and mediate 
inhibition of prostaglandin by COX 2 (Dave et al., 2008; Martinez and Moreno, 2000; 
Subbaramaiah et al., 1999). Moreover, treatment with resveratrol has been shown to 
attenuate MMP production thereby preventing progression of plaque formation as well as 
rupture of plaque cap (Dave et al., 2008).  
 Proteoglycan is an endogenous anti-inflammatory agent and its level is shown to 
be decreased during the autoimmune inflammation, however treatment with resveratrol 
has been shown to upregulate the level of proteoglycan thereby attenuating the 
pathological progression of autoimmune inflammation (Dave et al., 2008). Similarly 
inhibition of NFkB- a marker of autoimmune inflammation has been shown by 
resveratrol treatment in patients with increased risk of CVD (Kang et al., 2009; Karlsson 
et al., 2000; Leiro et al., 2004). With such diverse array of anti-inflammatory property 
packed into resveratrol, it makes resveratrol a novel therapeutic agent in the treatment 
and management of plaque stabilization and inhibition of thrombus formation thereby 
lowering the incidence of CVD significantly as well as improving the overall quality of 
life tremendously in patients with HF. 
1.10 Effect Of Resveratrol On Endothelial Protection 
 Bone marrow derived mononuclear cells (BMMCs) are reported to be major 
source of circulating stem cells. These cells are integral in the formation and repair 
mechanism of vessels. During injury or oxidative stress, these cells die rapidly thereby 
normal functioning of the blood vessels is compromised. Fortunately resveratrol has been 
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shown to be a major player in mediating the level of BMMCs by activating PI3K/AKT 
pathway. This hypothesis was tested by a study where they induced ischemia in the hind 
limb of ApoE KO rodent and resveratrol was able to attenuate the ischemia by decreasing 
the oxidative stress as well as inducing angiogenesis (Gan et al., 2009). Another study 
showed that resveratrol works through VEGF and causes protection in experimental 
models of oxidized EPCs (Lefevre et al., 2007). In addition, resveratrol has been shown 
to protect endothelial cells by induction of iNOS in macrophages (Arunachalam et al., 
2010; Cho et al., 2002) as well as via upregulating eNOS pathway (Klinge et al., 2008). 
Integrity of vascular wall is essential for the normal functioning of heart and resveratrol 
have successfully been shown to impart these protective effects through various 
mechanisms thereby making it a potential therapeutic agent for the treatment and 
management of HF (Lefevre et al., 2007; Wang et al., 2007; Xia et al., 2008).  
1.11 Protective Effects Of Resveratrol In Cardiac Hypertrophy And Heart 
Failure 
 A number of recent studies using rodent models of PO and VO induced HF 
reported successful regression of cardiac hypertrophy and dysfunction by (Behbahani et 
al., 2010; Thandapilly et al., 2010). Resveratrol has been shown to upregulate the level of 
eNOS/NO thereby causing vasodilation and mediating anti-hypertrophic effect of 
cardiomyocyte (Juric et al., 2007). Similarly resveratrol has been shown to mediate anti-
oxidative stress by activating AMPK and preventing LKB1 inhibition (Chan et al., 2004; 
Dolinsky et al., 2009; Langley et al., 2002). During decompensatory stage, cardiac 
remodeling causes excessive fibrosis, which further leads to apoptosis eventually 
resulting in cardiomyocyte deficiency that cannot be easily replaced. Fortunately 
 28 
resveratrol has been shown to actively repair the damaged DNA and stabilize the 
genome. Also by activating SIRT1, resveratrol has been shown to limit premature cellular 
ageing thereby promoting life span in failing myocytes (Langley et al., 2002; Pillai et al., 
2006). In patients with chronic HF, level of noradrenaline is increased due to decreased 
reuptake of catecholamine, however resveratrol has been reported to normalize the 
density of beta adrenoreceptor thereby restoring the sestivity of myocardium to 
catecholamines (Gaemperli et al., 2010). Resveratrol also has been reported to be able to 
reduce the infarct size in patients with MI (Burstein et al., 2007). Resveratrol has been 
reported to attenuate the frequency of cardiac arrhythmia by improving sympathetic 
neural remodeling (Xin et al., 2010). The reduction in the NE level by resveratrol also 
causes secondary effects on RAAS thereby improving cardiac performance and CO. A 
study demonstrated that Ca2+ uptake in the SR is controlled by SR Ca2+-ATPase, and 
this level of Ca2+ was found to be decreased in mice model of diabetic cardiomyopathy 
and in rats with MI. Resveratrol was able to attenuate this decline in the level of Ca2+ 
thereby maintain proper cardiac contractility (Schmidt et al., 2002; Sulaiman et al., 2010; 
Xin et al., 2010). Intriguingly, SIRT1 activation by resveratrol activates SERCA 2 level 
thereby further improving cardiac function. Therefore the findings of these studies 
suggest an invaluable role of resveratrol in mediating cardioprotection.  
1.12 Potential Role Of Resveratrol On Cardiomyocytes Regeneration 
After an acute or chronic insult, a number of cardiac myocytes undergo apoptosis 
however, for a normal functioning of the heart these losses needs to be repaired. 
Differentiation of these myocytes is therefore utmost essential.  Although, under normal 
physiological conditions, endogenous anti-oxidants keep working to ward off excessive 
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production of ROS however, they are vital signaling molecule and activate myogenic 
differentiation (Ding et al., 2008; Yang et al., 2008; Yang et al., 2009). Level of 
antioxidant enzymes such as Nrf2 and Ref 1 has been shown to be regulated by 
resveratrol, enhancing the regeneration of cardiac stem cells and hence mediating the 
cardioprotection during oxidative insult (Gurusamy et al., 2010). One such study 
pretreated the cardiac stem cells with resveratrol and upon their transplantation in the 
damaged heart, surprisingly improved the cardiac performance. Therefore it would be of 
significant clinical and therapeutic value by utilizing the cardioprotective effects of 
resveratrol in stem cells mediated cardioprotection.  
1.13 Role Of Resveratrol In Vascular Remodeling 
Cardioprotective effect of resveratrol has been shown in number of ways and via 
various pathways. One important aspect to consider is the maintenance of normal 
morphology of the vascular wall. Following an insult or injury not only the cardiac 
myocytes but also the blood vessels are greatly affected. Decrease in the endogenous 
anti-oxidant levels and activation of neurohormonal cascades further deteriorates the 
vascular wall morphology as shown in a study (Baur et al., 2006). Factors such as IL-18 
and MMP causes proliferation of vascular smooth muscle wall thereby narrowing the 
lumen which further causes increased systemic vascular resistance thereby causing 
vascular as well as cardiac remodeling. Resveratrol has been shown to cause vasodilation 
by increasing the level of endogenous anti-oxidant NO and attenuate the level of IL-18 as 
well as inhibit the activation of MMP (Ekshyyan et al., 2007; Venkatesan et al., 2009). 
Inhibition of DNA synthesis, cell cycle arrest and p53 induction are some of the 
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mechanisms by which resveratrol imparts its cardioprotective effects (Wang et al., 2006; 
Zou et al., 2000).  
1.14 Overall Objective, Specific Aims And Hypothesis 
Irrespective of the recent advance in the diagnostic tools and treatment modalities 
in the area of HF in the last decade, HF still remains the number one cause of morbidity 
and mortality in USA and imposes serious global healthcare affliction as well as socio-
economic burden. Current pharmacological such as diuretics, inotropic agents, ACE 
inhibitors, ARBs, aldosterone antagonists, and β-blockers coupled with improved 
diagnostic features although slow the progression of HF, but have reached their limits in 
improving patient prognosis (Bristow et al., 1996; Coats, 2002; Colucci et al., 1996). 
Thus, novel therapies are needed that act independently as well as in combination with 
abovementioned agents (Bristow, 2000a; From, 1998; Sabbah and Stanley, 2002; Tang 
and Francis, 2003). Given the importance of oxidative injury in the development and 
progression of HF, anti-oxidative approach to achieve better cardiac performance sounds 
reasonably attractive. 
 Thus, the aim of this study was to determine the antioxidant efficacy of resveratrol on 
the stressed heart, specifically to illuminate novel pathways leading to  the development 
of cardiac hypertrophy and failure. There were two specific aims: 
1. Examine the effect of resveratrol treatment on the development of LV hypertrophy, 
remodeling, and contractile dysfunction in response to pressure overload. 
2. To elucidate the underlying signaling cascades by which resveratrol is able to impart 
its cardioprotective effect. 
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Figure 1.1. Hypothetic natural history of stress-induced heart disease.	  Depicted 
four chamber sections of normal murine heart from surgically induced pressure-
overload hypertrophy and failure. 
Hill, J.A. Electrical remodeling in cardiac hypertrophy. 2003 Trends in 
Cardiovascular Med. 
Figure 1.2. Heart Failure Staging: ACC/AHA 2005 guideline for stages of heart 
failure. 
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Figure 1.3. Neurohormonal 
systems in heart failure (HF). A 
review of the Renal and 
Neurohormonal Effects of B-type 
Natriuretic Peptide- Andrew J. 
Burger. 
Figure 1.4. Ca2+ is the central regulator of cardiac contractility. As 
illustrated in the top section, Ca2+ generates signals by changing internal and 
external concentrations. In the heart there is a large store of Ca2+ in the SR. 
During contraction (middle section), a small increase of extracellular Ca2+, 
mediated by the L type Ca2+ channel induces a much larger release of Ca2+ 
into the cytosol from SR. Increased cytosolic Ca2+ initiates contraction by 
binding its effector TnC allowing for cross bridge formation. Ca2+ removal in 
relaxation (bottom section) is carried out primarily by the action of SERCAA2a 
and NCX, although the extent that each contributes varies between species. 
Solaro RJ. Regulation of Cardiac Contractility. San Rafael (CA): Morgan & 
Claypool Life Sciences; 2011. 
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Figure 1.5. Stages in the development of heart failure and recommended therapy 
by stage. 
ACCA/AHA 2005 Guideline for Diagnosis and Management of chronic HF in adult. 
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Figure 1.6. NADPH oxidase-dependent oxidative stress in failing heart. From 
pathogenic roles to therapeutic approach. NADPH oxidases serve as a major 
contrin=butor in producing reactive oxygen species (ROS) in myocardium and 
fibroblast. Oxidative stress is caused by increased ROS. 
Yanti Octavia et al. Free Radical Biology and Medicine Volume 52, Issue 2. 2012 
291-297 
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Figure 1.7. Schematic showing structure of resveratrol and some of its most 
potent effects. 
Slevin et al. Vascular Cell. 2012 
Figure 1.8. Sources of resveratrol. Resveratrol is a natural phytoalexin found in a 
number of different plants, including grapes, peanuts and mulberries. Resveratrol 
is produced by these plants in response to stress and fungal infection. 
Aggarwal et al. Role of resveratrol in prevention and therapy of cancer: preclinical 
and clinical studies. Anticancer Res. 2004 Sep-Oct;24(5A):2783-840 
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Figure 1.9. A schematic representation of ROS formation and its pathogenic 
effects.  These effects include increased levels of asymmetric dimethylarginine 
(ADMA), increased formation of reactive oxygen species (ROS), oxidative stress, 
reduced bioavailability of NO, inflammation, hypertrophy of vascular muscle, and 
changes in DNA methylation. The resulting changes include impairment of signaling 
by NO, endothelial dysfunction, reductions in maximum vasodilator capacity, and 
alterations in gene expression. 
Neil Baldwin et al. Advances in stroke. 2003. 
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Table 1. Effects of resveratrol on different cell signaling pathways.  
Huige Li et al. Cardiovascular effects and molecular targets of resveratrol. Nitric 
Oxide. 2012 
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Table 2. Effects of resveratrol in different animal model of cardiovascular disease 
along with concentration used. 
Huige Li et al. Cardiovascular effects and molecular targets of resveratrol. 
Nitric Oxide. 2012. 
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CHAPTER 2 
Material and Methods 
2.1 Pressure Overload Model 
 For the pressure-overload model, eight to ten weeks old (26-28 g) C57/ BL6 male 
mice were used in this study. (Harlan Sprague Dawley, USA). Surgical details of the 
TAC procedure are described elsewhere (Wojciechowski et al., 2010). Briefly, mice were 
kept in a temperature- and humidity-controlled room with a 12-h light:12-h dark cycle for 
1 week before creation of the PO model. Standard mice chow and tap water were 
available ad libitum. All mice were anesthetized for surgeries with 5% isoflurane carried 
by oxygen at a flow rate of 2 l/min. Mice were then maintained in surgical plane of 
anesthetic with 2% isoflurane. Hair on the surgical area was removed using hair remover 
lotion and incision site was disinfected using 100% alcohol and iodine.  
A midline thoracotomy was performed at the level of the suprasternal notch. 
Gently the ribs were retracted and isthmus was separated allowing direct visualization of 
the transverse aorta without entering the pleural space thereby avoiding the need for 
mechanical ventilation. A fine needle and 7-0 silk suture was used to pass under and 
around the transverse aorta between the right innominate and left common carotid 
arteries. A piece of 27-gauge needle piece was placed over the transverse aorta and 
quickly a knot was secured to the diameter of a 27-gauge needle yielding a 70-80% 
constriction. The needle and 7-0 silk suture was the retracted. Successful bands were
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snug while blood flow to the brain and body was maintained. The sternum, thoracic 
musculature and the skin incisions were closed by standard techniques with absorbable 
suture and auto clips.  
Sham operations on sex- and age-matched mice underwent exact same procedure 
as TAC with the exception of actual aortic banding and served as a control for all 
experimental groups. At 24 hours after surgery aortic-banded mice were randomly 
divided into two groups. One group of aortic-banded mice were administered resveratrol 
(100 mg·kg body wt−1·day−1) by oral gavage for a period of 4 wk while sham operated 
and the other group of aortic banded mice were given vehicle treatment (0.5ml water). 
All the three groups (sham-operated, aortic-banded; resveratrol- treated,) were 
maintained for a total of 4 wk. (Figure 2.1) 
2.2 Echocardiographic Assessment of Cardiac Structure and Function  
Two-dimensional-guided (2D) M-mode echocardiography of the mice was 
performed on days 0, 7, 14, 21 and 28, using Vevo 770 High-Resolution Imaging System 
with a 37.5-MHz high-frequency linear transducer (VisualSonics Inc. Toronto, ON, 
Canada) as previously described (Xing et al., 2012).  Briefly, mice were anesthetized 
with 3% isoflurane and maintained with 1.5% isoflurane in room air supplemented with 
100% O2. After the anterior chest was shaved, the animals were placed on a warming pad 
to maintain normothermia. Echocardiographic gel was warmed prior to use in order to 
avoid hypothermia. Care was taken to avoid excessive pressure on the thorax, which can 
induce bradycardia and result in severe deterioration of functional parameters and or even 
death. Two-dimensionally (2D) long axis images of left ventricle (LV) were acquired at 
the level of the aortic and mitral where the LV cavity is largest allowing adequate 
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visualization of the LV apex. Echocardiographic recording of anterior and posterior LV 
wall was done in M-mode at the speed of 21 frames per second. Images were acquired at 
the level of the papillary muscle tips, and measurements were then performed to obtain 
the LV internal dimension during systole (LVIDs; in mm), the LV internal dimension 
during diastole (LVIDd; in mm), LV posterior wall thickness during systole (LVPWs; in 
mm) and LV posterior wall thickness during diastole (LVPWd; in mm) according to the 
leading-edge method of the American Society of Echocardiography. LV percent ejection 
fraction (EF) and fractional shortening (FS) was calculated via VisualSonics 
Measurement Software. 
2.3 Isolation Of Mice Heart. 
After the 4-wk echocardiographic assessment, mice from all groups were weighed 
and anesthetized by using isoflurane before being euthanized. Toe pinch was performed 
to make sure the mice were totally unresponsive. Hearts and lungs were quickly isolated 
and washed in ice-cold saline and the wet weight of the heart (HW) and wet weight of the 
lung (LW) were measured as indices of cardiac hypertrophy and lung edema. Tissue was 
separated, flash-frozen in liquid nitrogen, and subsequently stored at −85°C until further 
experimentation. 
2.4 Preparation Of The Homogenate. 
LV tissue was pulverized and homogenized in a buffer containing 10 mM 
NaHCO3, 5 mM NaN3, and 15 mM Tris·HCl at pH 6.8 (10 ml/g tissue). This was 
aliquoted and frozen in liquid nitrogen before storage at −85°C. The buffer used for LV 
tissue homogenization also contained a cocktail of protease inhibitors consisting of (in 
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µM) 1 leupeptin, 1 pepstatin, and 100 phenylmethylsulfonyl fluoride to prevent protein 
degradation during the procedure. 
2.5 Histological And Immunochemical Analysis 
Hearts were exercised and washed with ice-cold 0.9% saline, fixed in 4% 
paraformaldehyde, and were embedded in paraffin. 5 µm thick paraffin sections were 
prepared using (Leica RM2030, rotary microtome) and stored at room temperature until 
further staining. Immunohistochemistry involved the use of microwave based antigen 
retrieval process. Using three changes of xylene and five chances of alcohol at varying 
concentration, sections were deparaffinized and the Texas Red-X conjugated wheat germ 
agglutinin (WGA) (Invitrogen Corp., Carlsbad, CA) staining was done to stain the 
membranes to acquire left ventricular cardiomyocyte cross-sectional area (CSA) as 
described elsewhere (Xing et al., 2012). Images were acquired by observing slides under 
the fluorescence microscope (Nikon Eclipse E600; Nickon In, Melville, NY) at 400 × 
magnification. By using Q capture software (MAG Corp., Pleasanton, CA), twenty fields 
of each section were randomly photographed and cardiomyocyte area was measured 
using Image-Pro Plus software (Media Cybernetics, Inc., Bethesda, MD).  
PO induced myocardial fibrosis was assessed by staining the sections for collagen 
with Masson’s Trichrome Kit (Poly Scientific, Bay Shore, NY). Myocardial sections 
from LV were deparaffinized, rehydrated and stained with products supplied in the kit 
according to the protocol provided by the manufacturer. Images were acquired under the 
light microscope (Nikon Optiphot-2; Nikon Inc., Melville, NY) at 200 × magnification. 
The relative fibrotic area (% of total area) was averaged from 20 fields of each section 
that were randomly photographed.  
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To access the extent of damage caused by inflammatory response, sections were 
stained for macrophage. Sections were deparaffinized, rehydrated and rat anti-mouse 
macrophage antibody Mac-2 primary antibody (1:200 dilution) (cedarlane,NC) along 
with staining kit (Immunocruz ABC staining system, santa cruz) and corresponding 
secondary antibody was used according to the protocol provided by the manufacturer. 
Sections were observed under light microscope (Nikon Optiphot-2; Nikon Inc., Melville, 
NY) at 200 × magnification. Twenty fields of each section were randomly photographed 
using Axio Vision 3.1 software (Carl Zeiss Inc., Maple Grove, MN). The number of (the 
brown stained cells) was counted by Image-Pro Plus software (Media Cybernetics, Inc., 
Bethesda, MD), and quantitative assessment of macrophage density was performed by 
counting the number of Mac-2 immunopositive cells and expressed as percentage change 
relative to control. 
Similarly staining for mast cells as a marker of inflammatory response was done 
using Toluidine blue O (Sigma Aldrich). The sections were stained with 0.1% toluidine 
blue for mast cell identification. Paraffin sections were deparaffinized, hydrated, and 
rinsed in deionized water according to the protocol provided by the manufacturer. 
Briefly, sections were placed in 1% acid alcohol for 3–5 min, followed by a transfer to 
0.5% toluidine blue solution for 15 min. The sections were then rinsed in deionized 
water, dehydrated in acetone, and cleared in acetone-xylene. Finally, the sections were 
mounted in permount and coverslipped. Images were acquired by observing under light 
microscope (Nikon Optiphot-2; Nikon Inc., Melville, NY) at 200 × magnification. 
Twenty fields of each section were randomly photographed using Axio Vision 3.1 
software (Carl Zeiss Inc., Maple Grove, MN). The number of (the blue stained cells) was 
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counted by Image-Pro Plus software (Media Cybernetics, Inc., Bethesda, MD). Mast cell 
density was assessed by counting all mast cells identified per section and expressed as 
average mast cell number in percentage change relative to control. 
Staining of 4-Hydroxy-2-Nonenal (4-HNE), a marker of lipid peroxidation, was 
performed with a mouse anti 4-HNE antibody (ab48506, Abcam Inc., Cambridge, MA) 
according to the protocol recommended by the manufacturer. Elaborate procedure is 
described elsewhere (Xing et al., 2012). Briefly, 5 µm thick paraffin sections were 
prepared using (Leica RM2030, rotary microtome) and stored at room temperature until 
further staining. Using three changes of xylene and five chances of alcohol at varying 
concentration, sections were deparaffinized. Immunohistochemistry involved the use of 
microwave based antigen retrieval process for 30 minute in citrate buffer. Sections were 
blocked using 5% serum at 20 degree for 20 minutes followed by incubation with 
primary antibody (1/25 dilution) for overnight at 4 degree and corresponding secondary 
antibody was used. Cardiomyocytes were stained with rabbit anti-tropomyosin 
I(ab55915, Abcam Inc, Cambridge, MA) and nuclei were stained with DAPI. Images 
were acquired by observing slides under the fluorescence microscope (Nikon Eclipse 
E600; Nickon In, Melville, NY) at 400 × magnification. By using Qcapture software 
(MAG Corp., Pleasanton, CA), twenty fields of each section were randomly 
photographed and quantification was done using Image-Pro Plus software (Media 
Cybernetics, Inc., Bethesda, MD). Relative fluorescent intensity was semi-quantified and 
represented as integrated optical density (IOD) with respect to the area measured. 
Staninig for 8- hydroxydeoxyguanosine (8-OHdG), a marker of DNA oxidization, 
was performed with a mouse anti 8-OHdG antibody (sc-660369, Santa Cruz 
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Biotechnology, Inc., Santa Cruz, CA), according to the protocol of the manufacturer. 
Detailed method is described elsewhere (Xing et al., 2012). Briefly, 5 µm thick paraffin 
sections were prepared using (Leica RM2030, rotary microtome) and stored at room 
temperature until further staining. Using three changes of xylene and five chances of 
alcohol at varying concentration, sections were deparaffinized. Immunohistochemistry 
involved the use of microwave based antigen retrieval process for 30 minute in citrate 
buffer. Sections were blocked using 5% serum at 20 degree for 20 minutes followed by 
incubation with primary antibody (1/25 dilution) for overnight at 4 degree and 
corresponding secondary antibody was used. Cardiomyocytes were stained with rabbit 
anti-tropomyosin I(ab55915, Abcam Inc, Cambridge, MA) and nuclei were stained with 
DAPI. Images were acquired by observing slides under the fluorescence microscope 
(Nikon Eclipse E600; Nickon In, Melville, NY) at 400 × magnification. By using 
Qcapture software (MAG Corp., Pleasanton, CA), twenty fields of each section were 
randomly photographed and quantification was done using Image-Pro Plus software 
(Media Cybernetics, Inc., Bethesda, MD). Relative staining area was quantified and 
represented as integrated optical density (IOD) with respect to the area measured. 
TUNEL staining on tissue sections by using In Situ Cell Death Detection Kit was 
done to access apoptosis, TMR red (Roche Applied Science, Indianapolis, IN) according 
to the protocol provided by the manufacturer. Detailed procedure is described elsewhere 
(Xing et al., 2012). Briefly, the sections were deparaffinized, rehydrated, microwaved for 
30 minutes for antigen retrieval and incubated with 50 µl TUNEL Reaction Mixture at 
37oC for 1 hr. A section was digested for 30 minutes with DNase (RNase-Free DNase 
Set, QIAGEN Inc., Valencia CA) for positive control and a negative control section was 
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only incubated with labeling solution. The apoptotic nuclei were labeled with TUNEL 
(red) all nuclei were counterstained with DAPI (blue) (Invitrogen Corp., Carlsbad, CA), 
and the F-actin was stained by Alexa Fluor® 488 phalloidin (green) (Invitrogen Corp., 
Carlsbad, CA). Images were acquired by observing slides under the fluorescence 
microscope (Nikon Eclipse E600; Nickon In, Melville, NY) at 400 × magnification. By 
using Qcapture software (MAG Corp., Pleasanton, CA), twenty fields of each section 
were randomly photographed and quantification was done using Image-Pro Plus software 
(Media Cybernetics, Inc., Bethesda, MD). TUNEL positive cells were quantified as a 
percent of all nuclei in the section of LV. 
2.6 Western Blotting And Protein Activity 
The protein content of sodium oxide dismutase  (SOD) was measured by SOD 
assay kit (Sigma, Switzerland) and Glutathione synthase (GSH) was measured by GSH-
Glo Glutathione assay kit (Promega, Madison, WI) according to the protocol provided by 
the company. 20/20 luminometer (Turner BioSystems, Sunnyvale, CA) was used to 
detect the total GSH activity while spectra max plus (Sunnyvale, CA) was used to detect 
the total SOD activity. Myocardial protein content of cleaved caspase-3 (Santa Cruz 
Biotechnology, Santa Cruz, CA), hypoxia inducible factor 1alpha (Hif-1α) (Novus 
Biologicals, Littleton, CO) from LV homogenates were determined by Western blot 
analysis as described previously (DiPette et al., 1989; Latronico et al., 2008; Zhang et al., 
2007). Briefly, total protein from LV tissue was extracted by T-PER tissue protein 
extraction reagent (Thermo Scientific, Rockford, IL).  Protein samples (25-30 µg) were 
fractionated by sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-
PAGE), then transferred to nitrocellulose membranes.  The membranes were probed with 
corresponding primary antibodies. Appropriate HRP-conjugated secondary antibodies 
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were used and the antibody-antigen complexes in all membranes were detected by the 
ECL PLUS Detection Kit (Thermo Scientific, Rockford, IL). The expression of these 
proteins was quantified with Scion Image (NIH) and adjusted to β-actin. 
2.7 Statistical Analysis 
Data were expressed as mean ±SD. Differences among groups were tested by 
one-way ANOVA followed by Bonferroni’s multiple comparison post hoc test. A value 
of p<0.05 was considered significantly different. 
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CHAPTER 3 
RESULTS 
3.1 Hemodynamics, Survival Rate, Body Weight, Heart Weight And Heart 
Rate Prior To TAC 
There were no operative deaths within 24 h after TAC or SHAM operation. 
Baseline blood pressure was taken by tail cuff method (MC4000 Blood pressure analysis 
system). No significant difference in the systolic blood pressure was observed among the 
three groups. Similarly no significant difference in the heart rate was found among the 
three groups. There was no significant increase in mortality of any of the group. However 
autopsy revealed that mice that died before 4 weeks of TAC had apparent signs of heart 
failure (data not shown). 
3.2 Assessment Of Body, Heart And Lung Weights After TAC. 
Analysis of surviving mice after 4 weeks of chronic pressure overload showed 
that heart weight (HW) in ratio of body weight (BW) were significantly greater in TAC 
mice compared to sham-operated mice (4.9 ±0.3 vs 8.8 ±1.1). Similarly the ratio of lung 
weight to body weight (LW/BW) was also found to be significantly higher in TAC mice 
compared to sham.  and (4.80 ±0.53 vs 10.28 ±1.4). The increase in (HW/BW) and 
(LW/BW) ratios after TAC were significantly attenuated in the TAC+RSV treatment 
group (7.2 ±0.3) and (6.2 ± 1.8) . Figure 3.1 
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3.3 Resveratrol Treatment Improves Cardiac Function 
Echocardiography clearly demonstrated ventricular hypertrophy and LV 
dysfunction induced by pressure overload (PO) in (TAC) mice. Figure 3.2 shows typical 
representation of the echocardiogram showing cardiac dimensions whereas Figure 3.3A-F 
illustrates representative echocardiograms from the three groups taken over the course of 
4 weeks.  
Cardiac structure assessment involved measurements of LVID, LVPW, IVS, %EF 
and %FS at both systole and diastole. After 4 weeks of TAC, LV internal dimensions 
during diastole (LVID;d) was significantly increased in TAC mice (5.16±0.26) compared 
to sham operated (4.08 ±0.10). Resveratrol treatment was able to significantly attenuate 
this adverse parameter (4.39 ±0.12).  Similarly LV internal dimension during systole 
(LVIDs) were significantly increased in TAC mice compared to sham-operated. 
(3.4±0.03 vs 2.46±0.09). Remarkably, diastolic impairment was significantly attenuated 
with resveratrol treatment in TAC+RSV group (2.72±0.08). LV systolic function, as 
assessed by LV ejection fraction (%EF), fractional shortening (%FS) were significantly 
decreased in the TAC mice to a greater extent relative to sham-operated mice.(64.2 ±2.0 
VS 33.13 ±1.87 and 46.46 ±2.41 vs 26.15 ±1.97) Interestingly, resveratrol treatment 
significantly attenuated the sharp decline of both parameters (52.4 ±4.37 and 35 ±2.63) 
and maintained cardiac performance. 
3.4 Attenuation Of Cardiac Hypertrophy And Fibrosis By Resveratrol. 
LV hypertrophy assessed by WGA staining was significantly greater in TAC mice 
(221.7 ±21.43) compared to sham treated (108.02 ±12.85). However the degree of 
hypertrophy was significantly attenuated in RSV treated mice (187 ±11.9) as compared to 
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TAC alone. Figure 3.4A. Similarly LV interstitial and perivascular fibrosis as determined 
by Masson’s trichrome staining was found to be significantly higher in TAC mice (2.23 
±0.3 and 0.87 ±0.1) respectively as compared to sham treated mice (0.28 ±0.05 and 0.10 
±0.06). However this increase in fibrosis was significantly attenuated in RSV treated 
group as compared to TAC alone (1.29±0.20 and 0.65±0.13).  Figure 3.4 B 
3.5 Anti-inflammatory Activity Mediated By Resveratrol  
Macrophage infiltration was found to be significantly increased after 4 weeks of 
TAC (14.8 ± 0.06 ) compared to sham operated (1.71 ± 0.01). Treatment with resveratrol 
was found to attenuate macrophage infiltration in the heart of TAC+RSV (10.43 ± 0.03) 
mice as compared to TAC alone. Figure 3.5 A 
Similarly pressure overload induced increase in the number of cardiac mast cells 
were significantly higher in TAC group (12.5 ± 0.03) compared to sham operated (2.56 ± 
0.02). However treatment with resveratrol was found to attenuate mast cells infiltration as 
well in the heart of mice as compared to TAC alone (7.96 ± 0.03). Figure 3.5 B 
3.6 Resveratrol Attenuates Oxidative Damage In TAC Induced Heart. 
Anti-oxidative property of resveratrol in hearts of TAC induced PO mice was 
assessed by measuring myocardial biomarker expression of 4-hydroxynonenal (4-HNE) 
which is a marker of oxidative index of lipid peroxidation, and 8-hydroxydeoxyguanosine 
(8-OHdG), a marker of DNA damage induced by oxidative stress. These myocardial 
biomarkers of oxidative stress 4HNE were significantly increased in the mice that 
underwent TAC procedure (18.4±3.1%) relative to sham surgery (3.38±1.0%). 
Resveratrol treatment however, was able to attenuate the upregulation of 4-HNE in the 
TAC+RSV group (14.4±1.9%). Figure 3.6 A 
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Similarly, the oxidative marker 8-OHdG level was sharply upregulated in the 
TAC mice (22.7±3.1%) compared to sham counterparts (2.8±1.0%). Again, treatment 
with resveratrol was able to significantly attenuate this pathological damage in 
TAC+RSV group (16.22±0.9%). Figure 3.6 B 
3.7 Resveratrol Prevents Cardiomyocyte Apoptosis 
Decrease in the LV function with chronic pressure overload induced LV 
hypertrophy may be mediated by excessive apoptosis resulting in a reduction in total 
contractile units and LV mass. TUNEL immunohistochemical shaining was performed to 
access the cardiomyocyte apoptotic death. Treatment with resveratrol may prevent 
myocyte apoptosis thereby maintaining LV mass. As expected, the number of apoptotic 
nuclei in the heart of TAC mice (0.13±0.01) was significantly greater than in sham 
operated mice (0.01±0.007). Resveratrol treatment was able to successfully attenuate the 
ongoing apoptosis to a significant level (0.09±0.01) relative to untreated group. Figure 
3.7 
3.8 Resveratrol Protects Heart Failure By Inhibiting Hypoxia And Inducing 
Antixoidative Enzymes. 
Interestingly, in line with the maintained attenuation of elevated TUNEL positive 
nuclei, myocardiac level of cleaved caspase-3 was significantly also found to be 
significant up-regulated in TAC mice (177±3.2) compared to sham operated (154±3.1). 
attenuated in the  TAC+RSV group(166±7.9 ) Figure 3.8. The results between western 
blot and immunostaining show a strong positive correlation. 
In addition, we analyzed the cardiac expression of the angiogenic factor HIF-1α.  
It has been reported that VEGF and HIF1α is up-regulated in the pressure overload-
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induced hypertrophic WT hearts (Hilfiker-Kleiner et al., 2005; Sano et al., 2007). In the 
TAC WT hearts there was a significant increase in HIF-1α (176±10 ) levels as compared 
to sham-operated mice (83.2±4.4). The increase in HIF-1α may be due to high demand of 
oxygen to hypoxic heart and may play a role in the increase in capillary density through 
VEGF. Treatment with resveratrol however attenuated the HIF-1α level in TAC+RSV 
group (115±7.4) suggesting resveratrol may be mediating anti-hypoxic activity through 
other pathway. Figure 3.8 
Likewise the levels of antioxidative enzymes such as SOD  and GSH was found 
to be sharply declined in the TAC mice (7.3±0.9 U/mg and 5.2±0.2 nM/mg ) compared to 
sham surgery(10.7±1.3 U/mg and 8.5±0.27 nM/mg) . Resveratrol was able to 
successfully attenuate this decline to a significant extent in RSV treatment group relative 
to TAC alone (9.4±0.4 U/mg and 6.69±0.32 nM/mg).  Figure 3.9  
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Figure 3.1. Assessment of body, heart and lung weight after TAC. Groups 
(n=7/group) of WT mice were subjected to either SHAM or TAC surgery. Wet weight 
of heart and lung was recorded as an index of cardiac hypertrophy and heart failure at 
day 28 post surgery. (A), Heart weight/body weight (HW/BW) ratio (B) Lung 
weight/body weight ratio (LW/BW). Both HW/BW and LW/BW ratio were found to 
be significantly increased in TAC mice compared to SHAM. Resveratrol treatment 
however attenuated this pathological change. Values are expressed as mean±SD. 
p<0.05 was considered statistically significant.  
Figure 3.2: Representative image acquired from 2D echocardiogram (Vevo 770) 
showing the internal dimentions of LV.  LVAD, LVPW, LVID parameters were 
compared between sham operated,TAC and TAC+RSV treated at 0,7,14, 21 and 28 
day respectively. 
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Figure 3.3. A.  Resveratrol treatment attenuates cardiac contractile dysfunction 
in PO mice. Groups (n=7/group) of WT mice were subjected to either SHAM or TAC 
protocol and parameter for left ventricular inter diameter during systole was obtained 
at given time points.  Values are expressed as the mean ± SD.  * p<0.05 vs SHAM, ¥ 
P<0.05 vs T+R.   
Figure 3.3. B.  Resveratrol treatment attenuates cardiac contractile dysfunction 
in PO mice. Groups (n=7/group) of WT mice were subjected to either SHAM or TAC 
protocol and parameter for left ventricular inter diameter during diastole was obtained 
at given time points.  Values are expressed as the mean ± SD.  * p<0.05 vs SHAM, ¥ 
P<0.05 vs T+R.   
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Figure 3.3. C.  Resveratrol treatment attenuates cardiac contractile dysfunction 
in PO mice. Groups (n=7/group) of WT mice were subjected to either SHAM or TAC 
protocol and parameter for left ventricular posterior wall thickness during systole was 
obtained at given time points.  Values are expressed as the mean ± SD.  * p<0.05 vs 
SHAM, ¥ P<0.05 vs T+R 
Figure 3.3. D.  Resveratrol treatment attenuates cardiac contractile dysfunction 
in PO mice. Groups (n=7/group) of WT mice were subjected to either SHAM or TAC 
protocol and parameter for left ventricular posterior wall thickness during diastole was 
obtained at given time points.  Values are expressed as the mean ± SD.  * p<0.05 vs 
SHAM, ¥ P<0.05 vs T+R.   
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Figure 3.3. E.  Resveratrol treatment attenuates cardiac contractile dysfunction 
in PO mice. Groups (n=7/group) of WT mice were subjected to either SHAM or TAC 
protocol and parameter for percent change in ejection fraction was obtained at given 
time points.  Values are expressed as the mean ± SD.  * p<0.05 vs SHAM, ¥ P<0.05 vs 
T+R.   
	  
Figure 3.3. F.  Resveratrol treatment attenuates cardiac contractile dysfunction in 
PO mice. Groups (n=7/group) of WT mice were subjected to either SHAM or TAC 
protocol and parameter for percent change in fractional shortening was obtained at 
given time points.  Values are expressed as the mean ± SD.  * p<0.05 vs SHAM, ¥ 
P<0.05 vs T+R.   
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Figure  3.4 (A) TAC induced PO causes  exacerbation of  cardiac hypertrophy.   
WT mice were subjected to TAC or sham-surgery. Upper panel representative WGA 
staining of LV sections (400x magnification) in sham control, aortic banded mice 
treated with or without resveratrol at day 28 post surgery). Quantitation of myocyte 
surface area is shown in lower left panel. Values are expressed as the mean ± SD.  * 
p<0.05 was considered statistically significant. The number of hearts (n=6/group).  
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Figure 3.4 (B): Resveratrol treatment significantly attenuates exacerbation of 
cardiac fibrosis following TAC. A and C. Myocardial fibrotic area was measured 
from sham, TAC and Tac+Rsv treated mice  and  analysis of digital images of sections 
stained by Masson’s trichrome kit was done at day 28.  In the upper panel 
representative photomicrographs of fibrotic areas of  LV  interstitial fibrosis and lower 
panel showing LV perivascular fibrosis. (200x magnification). Values are represented 
as a percentage of total microscopic area per heart. The numbers (n=6/group) 
represents the number of sham and TAC hearts analyzed. Values are expressed as the 
mean ± SD. * p<0.05 was considered statistically significant. 
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Figure 3.5(A): Resveratrol attenuates exacerbation of inflammation following 
TAC. Groups (n=6/group) of WT mice underwent either SHAM or TAC protocol. 
Upper panel, representative immunohistochemical staining of macrophage with anti-
macrophage antibody Mac-2 (brown color) from LV sections of sham, TAC and 
TAC+RSV treatment mice  at day 28 (200x magnification). Lower panel, slides were 
quantified and depicted as percent macrophage cells with respect to control group. 
Values are expressed as the mean ± SD. * p<0.05 was considered statistically 
significant. 
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Figure 3.5 (B): Resveratrol attenuates exacerbation of inflammation following 
TAC. Groups of mice (n=6/group) underwent SHAM or TAC protocol. Upper panel, 
representative staining of mast cells with toluidine blue (blue color) from LV sections 
of sham, TAC and TAC+RSV treatment mice  at day 28 (100x magnification).  Lower 
panel, slides were quantified and depicted as percent mast cells with respect to control 
group. Values are expressed as the mean ± SD. * p<0.05 was considered statistically 
significant. 
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Figure 3.6 (A): Exacerbation of oxidative stress in TAC induced PO mice heart.  
Upper panel, representative  images of 4-HNE staining of LV sections at day 28 from 
TAC, sham mice and Rsv treated mice. Lower panel- level of 4-HNE was semi-
quantification by measuring IOD of six randomly chosen fields in each myocardial 
tissue section. Areas shown in red are positive for 4-HNE. Cardiomyocytes is stained 
green using anti-Tropomyosin I and nuclei in blue were labeled with DAPI. 
(n=6/group).* p<0.05 was considered statistically significant. 
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Figure3.6 (B): Exacerbation of oxidative stress in TAC induced PO mice heart. 
Upper panel  representative  images of 8OHdG staining of LV sections at day 28 from 
TAC, sham and Tac+Rsv treated mice. Lower panel- level of 8-OHdG was semi-
quantification by measuring IOD of six randomly chosen fields in each myocardial 
tissue section. Areas shown in red are positive for 8OHdG. Cardiomyocytes is stained 
green using anti-Tropomyosin I and nuclei in blue were labeled with DAPI. 
(n=6/group). * p<0.05 was considered statistically significant. 
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Figure 3.7: Effect of resveratrol on myocardial apoptosis in TAC induced PO 
mice heart.  Representative images of TUNEL staining of left ventricular are shown 
in upper panel.  Quantification of TUNEL positive cells are shown in lower panel. 
Apoptotic nuclei in TAC hearts were quantified by using image pro plus and 
represented as percent of total nuclei in the section of LV. Apoptotic nuclei shown in 
red, myocardium green and nuclei in blue. (400x magnification). (n=6/group). * 
p<0.05 was considered statistically significant. 
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Figure 3.8: Resveratrol protects heart failure by inhibiting apoptosis and hypoxic 
damage. Group (n=7/group) of WT mice were subjected to either sham or TAC 
surgery and one group was treated with resveratrol for 4 weeks. LV tissue was 
extracted and processed for western blot analysis for caspase 3 and HIF1-α, 
normalized to β-actin as control for equal loading .  Each lane contained 30 µg of 
protein. Lower panel-representative quantitation by densitometric tracing of protein 
bands (n= 3/group). * p<0.05 was considered statistically significant. 
	  
Figure 3.9: Treatment with resveratrol causes upregulation of anti-oxidative 
proteins in the heart. Group (n=7/group) of WT mice were subjected to either sham 
or TAC surgery and one group was treated with resveratrol for 4 weeks. Tissue was 
extracted and processed for total activity measurement at day 28. A: Quantitation of 
total tissue SOD activity (U/mg protein). B: Quantitation of total GSH content in the 
cardiac tissue (nM/mg protein). * p<0.05 was considered statistically significant. 
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CHAPTER 4 
DISCUSSION 
Prevention of cardiac structural and functional alterations by resveratrol treatment 
in experimental model of pressure overload created by TAC has been reported (Juric et 
al., 2007). Similarly regression of PO–induced cardiac hypertrophy and its deleterious 
consequences on heart function have also been reported previously in resveratrol-treated 
abdominal aortic-banded rats. (Li et al., 2005). Thus, it appears that resveratrol is 
beneficial in treating pathological pressure overload conditions that include hypertension. 
The main purpose of this study was to investigate the use of resveratrol as a 
potential alternative therapy for PO-induced HF. It has been firmly established that 
sustained chronic PO causes the activation of various oxidases which in turn causes 
increased ROS formation to induce cardiac hypertrophy, including cardiac myocyte 
hypertrophy, myocardial fibrosis and apoptosis leading to heart failure (El Hasnaoui-
Saadani et al., 2013). Given the critical role of resveratrol in antioxidant defenses, it was 
not surprising to find that resveratrol is cardio protective by decreasing oxidative damage 
in the heart. 
The significant findings of this study were that resveratrol treatment resulted in 1) 
significant attenuation of myocardial dysfunction; 2) prevention of cardiac myocyte 
against oxidative stress damage including attenuation of cardiac hypertrophy, fibrosis, 
inflammation and apoptosis, 3) upegulation of anti-oxidative proteins thereby combating  
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the oxidative injury. These beneficial effects of resveratrol occurred despite the continued 
presence of cardiac hypertrophy and hypertension in this model and if left untreated 
would ultimately result in LV dilation and overt heart failure. 
4.1 TAC-induced PO Mice Presents Signs Of Heart Failure. 
Four weeks after TAC surgery, mice developed PO induced concentric cardiac 
hypertrophy and decreased cardiac performance characterized by significant change in 
LV wall thickness, %EF, %FS leading to diastolic dysfunction. These results are 
consistent with previous studies and validate the experimental models used in this study 
(Juric et al., 2007; Li et al., 2005; Wojciechowski et al., 2010). 
4.2 Treatment With Resveratrol Improves Cardiac Function And Enhances 
Survival. 
Echocardiographic analysis revealed that that the WT hearts developed adverse 
structural remodeling and progressive dilation following induction of PO. This led to a 
significant reduction of EF and FS as well as a significant increase in the LW/BW ratio, a 
strong indication that these hearts were beginning to fail. The adverse remodeling and 
dilation was markedly exacerbated in the TAC hearts resulting in an even more 
pronounced decline in FS and a sharp increase in the LW/BW ratio by day 28 compared 
to the RSV treated. Additional evidence for the increased vulnerability of the TAC hearts 
to PO-induced heart failure is provided by the increased HW/BW ratio and 
cardiomyocyte size (CSA) in the TAC mice compared to their WT counterparts. 
Resveratrol treatment attenuated concentric remodeling by normalizing LVPW thickness 
both at systole and diastole. These beneficial effects of resveratrol in attenuating PO-
induced cardiac hypertrophy are consistent with other recent study that demonstrated 
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anti-hypertrophic effects of RSV in a rat model of PO-induced cardiac 
hypertrophy  (Wojciechowski et al., 2010). In this model, chronic RSV administration 
(2.5mg/kg bw) for 28 days was ensued. Echocardiographic and histopathological studies 
clearly showed marked deterioration in the cardiac function characterized by significant 
increment in the LV wall thickness and reduction in the cardiac function parameters as 
compared to sham or vehicle treated rats. Treatment with RSV was found to regress 
cardiac hypertrophy and dysfunction significantly. 
4.3 Resveratrol Treatment Induces Anti-oxidative Enzymes And Protects 
Against Oxidative Damage In Pressure Overloaded Mice Heart.  
Reactive oxygen species play an integral role in the development of inflammation 
and promote oxidative stress during hypertension (DeMarco et al., 2010). Another 
characteristic of resveratrol is anti-inflammation. Resveratrol not only modulates 
biochemical responses of polymorphonuclear leukocytes by interfering with the release 
of inflammatory meaditors but also suppresses the activity of macrophages (Sharma et 
al., 2007). The inflammatory response of the heart to pressure overload, as determined by 
macrophage infiltration was significantly higher levels in the TAC mice compared to 
their WT counterparts. This response is likely initiated by multiple pathways through 
increased oxidative stress, inhibition of cyclooxygenase (COX) and activation of the 
potent pro-inflammatory NF-κB system. Our study and other have shown that RSV 
attenuates the generation of ROS and inhibits macrophage infiltration (Kang et al., 2009; 
Karlsen et al., 2010; Leiro et al., 2005). Macrophage infiltration in TAC+RSV group 
dropped significantly indicating that in the absence of control over ROS production, there 
 68 
is a marked acceleration of the pathophysiological mechanisms that underlie the 
development of heart failure. 
  Similarly, mast cells have been implicated in the pathogenesis of HF by 
degranulating myocardial collagen and inducing fibrosis in response to infectious and 
inflammatory stimuli (Matsumori et al., 1994). Although found mainly in the skin, 
gastrointestinal tract, and airways, they are normally known to reside in cardiac tissue 
(Mina et al., 2013). Interestingly, levels of mast cells show a similar increase following 
the TAC procedure. This increase in mast cell number was strikingly higher in TAC 
compared to sham treatment. However, treatment with RSV was able to attenuate this 
mast cell infiltration significantly as compared to TAC alone.   
4.4 Resveratrol Exerts Marked Anti-fibrotic Property In TAC Induced PO 
Mice Heart. 
Consistent with the enhanced inflammatory response in the TAC mice compared 
to their WT counterparts, we also found striking increase in both interstitial and 
perivascular fibrosis in the pressure overloaded TAC hearts. This is most likely the 
primary cause of the significant deterioration of cardiac function. These data clearly 
indicates that the PO-induced fibrosis seen in the TAC mice is markedly increased 
compared to sham surgery. This may be in part, by necrotic cell death. There is a 
significant increase in LV apoptosis in the TAC WT mice compared to the sham mice. 
While myocyte apoptosis is well documented in heart failure and can reduce the force-
generating capacity of the myocardium (Juric et al., 2007), apoptotic cells are scattered 
across the wall of the chamber and are usually found as single cell losses. Indeed, 
replacement fibrosis in heart failure is the result of multiple diffuse foci that contain a 
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much larger number of dead cells than seen in apoptosis. While necrosis is not as well 
studied as apoptosis, it is now clear that this is a tightly regulated process. In heart failure, 
it appears that necrotic cell death is triggered at the level of the mitochondria by multiple 
factors including sympathetic and Ca2+ overload, oxidative and metabolic stress, and 
hypoxia (Schmidt et al., 2002). Several lines of evidence indicate that RSV has 
significant anti-apoptotic activity, both in vivo and in vitro, that is mediated by the 
inhibition of NF-κB, p53, Enos and PGC-1α via activation of SIRT1 pathways which 
stimulate survival pathways (Rodgers et al., 2005; Vaziri et al., 2001; Yeung et al., 2004).  
4.5 Exaggeration Of Cardiomyocyte Hypoxia In TAC Mice Is Attenuated 
With Resveratrol Treatment 
In addition, we analyzed the cardiac expression of the angiogenic factors  HIF-1α. 
Accumulating evidence has demonstrated that during development of cardiac 
hypertrophy, a mismatch between the number of capillaries and the size of 
cardiomyocyte develops, leading to myocardial hypoxia and subsequent cell death 
(Maeda et al., 2013).  It has been reported that HIF1α and VEGF were up-regulated in the 
pressure overload-induced hypertrophic WT hearts (Hilfiker-Kleiner et al., 2005; Sano et 
al., 2007).  In the present study, we found that TAC  resulted in significant increase in 
HIF-1α level which might have predisposed cardiomyocytes vulnerable to pressure 
overload induced cardiomyocyte apoptosis.  However treatment with RSV protected 
cardiomyocytes against hypoxia induced injury and death.  The angiogenic effect of RSV 
found in this study was consistent with other observations that RSV increased 
angiogenesis during ulcer and wound healing (Razban et al., 2012).  
 70 
Past and present studies have shown a growing consensus pointing towards NO as 
an endogenous anti hypertrophic molecule (Kempf and Wollert, 2004). It would be 
therefore beneficial to explore its potential in combating cardiac hypertrophy. Endothelial 
dysfunction (characterized as an impairment of endothelium-dependent relaxation) is 
known for structural changes in vasculature leading to endothelial dysfunction and 
ultimately hypertension. Several studies have shown that treatment with resveratrol 
results in enhancement of agonist-stimulated , endothelium dependent relaxation 
(Mizutani et al., 2000; Silan, 2008; Zhang et al., 2009). This improvement is largely 
attributable to NO derived from endothelial NO synthase (Enos) and is mediated through 
multiple mechanisms  (Li and Forstermann, 2009a, b). eNOS serves as a vital role in 
regulating beta-adrenergic transduction system and therefore cardiac function where 
chronic activation of beta-adrenergic receptor results in cardiac hypertrophy (Buys et al., 
2007). Given the role of resveratrol in mediating oxidative stress by upregulating 
endothelial nitric oxide in PO mice model of HF (Juric et al., 2007). Our results fit well 
with the anti-hypertrophic and cardioprotective roles of NO as we observed that 
resveratrol treatment significantly attenuated cardiac hypertrophy and as well as 
prevented contractile dysfunction as compared to TAC alone.  
Moreover it should be noted that resveratrol may also indirectly improve cardiac 
energy metabolism through its vasorelaxing effect, which could ameliorate perfusion and 
enhance oxygen and substrate delivery to the heart and the periphery. Finally, the 
beneficial cardiovascular and metabolic effects of resveratrol could also result from its 
phytooestrogenic properties. As a polyphenolic compound, resveratrol has been shown to 
be scavenger of hydroxyl, superoxide (Hung et al., 2002). Resveratrol induces 
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antioxidant enzymes in cardiovascular tissue (Cao and Li, 2004). SOD catalyze the 
dismutation of superoxide into hydrogen peroxide, which is further inactivated by 
glutathione (Forstermann, 2010). However it remains largely unclear as to how 
resveratrol causes induction of these antioxidant enzymes. Recent studies have 
demonstrated that overexpression of SIRT 1 leads to upregulation of SOD (Ungvari et al., 
2009). Consistent  with above study, our results show that PO causes myocardial levels of 
SOD and GSH to decrease dramatically relative to sham operated. Treatment with 
resveratrol however was able to induce the level of antioxidants and protect 
cardiomyocyte from oxidative injury. Resveratrol has also been reported to reduce 
oxidative stress by inhibiting ROS production through NADPH oxidase (NOX) system 
(Forstermann, 2010). 
4.6 Mode Of Action Of Resveratrol In Mediating Anti-oxidative Property 
Attenuation of hypertrophic response and also delaying the transition from 
hypertrophy to heart failure has been shown to be mediated by LKB1/AMPK pathway 
(Dolinsky et al., 2009).  LKB1 is an upstream kinase of AMPK and it inhibits cardiac 
remodeling by preventing angiotensin II –induced myocardial fibrosis. Oxidative stress 
has been reported to regulate LKB1/AMPK pathway. Lipid peroxidation product such as 
4-HNE is elevated during oxidative stress (Dolinsky et al., 2009). 4-HNE forms covalent 
adducts with LKB1 leading to inhibition of LKB1/AMPK signaling and activation of 
Mtor/p70s6 kinase mediated protein synthesis and cardiac myocyte growth. Treatment 
with resveratrol has been shown to prevents 4HNE modification of LKB1/AMPK 
signaling by blunting prohypertrophic p70S6 kinase response thereby attenuating left 
ventricular hypertrophy (Dolinsky et al., 2009). Consistent with the above mentioned 
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study, our results show a sharp induction of 4-HNE level in TAC mice compared to sham 
operated. However this upregulation of 4-HNE level was attenuated sharply with 
resveratrol treatment. 
4.7 Anti-apoptotic Potential Of Resveratrol. 
In failing heart, decompensation due to the chronic PO and cardiomyocyte 
deficiency due to fibrosis and apoptosis turns to be the predominat problem. Under such 
condition, resveratrol has been thought to potentiate an active DNA repair process instead 
of an inhibited protein synthesis, which preserves the genomic stability of cardiomyocyte. 
Oxidative DNA damage in cardiomyocyte was assessed to to determine extent of 
oxidative stress in PO hearts. 8OHdG and TUNEL positive stained nuclei were 
determined as an indicator of oxidative DNA damage in the heart. The induction of 
8OHdG and immunopositively stained TUNEL nuclei indicated the presence of oxidative 
DNA damage. Consistent with others findings, (Sin et al., 2013) our results demonstrated 
a significant oxidative damage in TAC hearts compared to sham. However this induction 
was significantly attenuated with resveratrol treatment. The content of 4HNE was 
positively correlated with the number of 8OHdG and TUNEL immunopositive nuclei. 
4.8 Clinical Relevance 
Irrespective of numerous protective roles mediated by resveratrol in various 
diseases and experimental settings, it has not yet achieved the clinical significance 
through mass human clinical trials. Variety of fruits and food has been shown to contain 
resveratrol and is expected to keep people healthy by scavenging free oxygen radicals. 
However due it its short half-life and rapid metabolizing property, the potency of 
resveratrol cannot be maintained for long in the body thereby ways to improve its 
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bioavailability either by blocking its rapid metabolism or developing analogs which can 
potentiate similar yet long lasting effects is needed (Baur and Sinclair, 2006). Although 
there are various ongoing research whose primarily focus have been the structure of 
resveratrol (Lagouge et al., 2006), yet great deal of difficulties and challenges are 
encountered in the process of screening the effective elements of resveratrol in vivo and 
determining the differences between in vivo and in vitro results (Baur and Sinclair, 
2006). Another challenge is to figure out the effective yet safe dose in humans because 
the dose at which resveratrol shows its potential to inhibit or treat certain disease might 
not apply on humans simply by extrapolating the figure or weight conversion (Reagan-
Shaw et al., 2008). There has been significant increase in the number of publications 
involving protective effects of resveratrol in diverse disease and experimental settings, 
while on the other side numerous clinical trials are ongoing regarding the safety and 
efficacy of this molecule. Fortunately, several phase one study have been completed 
among which one showed potential decrease in circulating IGF-1 as well as IGF- binding 
protein 3 in normal human subjects as compared to pre-dosing values (Patel et al., 2011). 
Another study involving resveratrol in human subjects showed marked attenuation of 
reactive oxygen species leading to downregulation of tumor necrosis factor-α as well as 
inflammation markers interleukin-6 and C-reactive protein (Ghanim et al., 2010). So far 
resveratrol has not been shown to cause significant side effects (Boocock et al., 2007; 
Camins et al., 2010; Ghanim et al., 2010; Patel et al., 2011) however, some increase in 
blood bilirubin and alanine aminotransferases were noted in healthy volunteers receiving 
high doses (Almeida et al., 2009). Some degree of headache, dizziness, myalgia and 
epididymitis were also reported in a rising multiple-dose study in healthy volunteers 
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providing the evidence that resveratrol is well tolerated under conditions of repeated 
administration (Almeida et al., 2009). 
With such diverse protective effects, resveratrol is expected to do much more 
wonders in treatment and management of HF. In the setting of cardiovascular disease, by 
correcting the oxidative stress, resveratrol sharply regulates the pathogenic factors like 
inflammation, hyper coagulation, obesity, dyslipidemia, atherogenic plaque formation, 
hyperglycemia, apoptosis, fibrosis and cardiac dysfunction thereby providing ample 
evidence of being prime candidate for treatment of heart failure.  However, much 
research is needed to finally achieve targeted therapy, treat cardiovascular diseases and 
increase the quality of life in HF patients.  
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